http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Kim, Dong‐,Wook,Tan, Eugene Y.,Jin, Yu,Park, Sahee,Hayes, Michael,Demirhan, Eren,Schran, Horst,Wang, Yanfeng Blackwell Publishing Ltd 2011 British journal of clinical pharmacology Vol.71 No.2
<P> <B>WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT</B> </P><P>• Imatinib mesylate, a tyrosine kinase inhibitor, exhibits a weak competitive inhibition on paracetamol (acetaminophen) <I>O</I>‐glucuronidation with an inhibition constant (<I>K</I><SUB>i</SUB>) value of 59 µ<SMALL>m</SMALL>. However, the clinical significance of the inhibition has not been evaluated. The pharmacokinetics of imatinib have been studied in white patients with chronic myelogenous leukaemia (CML), but not in Korean patients with CML.</P><P> <B>WHAT THIS STUDY ADDS</B> </P><P>• Imatinib (400 mg once daily) had no clinically relevant effect on the plasma exposure and the pharmacokinetics of paracetamol (1000 mg once daily) in patients with CML.</P><P>• The pharmacokinetic profile of imatinib in Korean patients with CML was similar to that in whites.</P><P><B>AIMS</B> The major objective of the present study was to investigate the effect of imatinib on the pharmacokinetics of paracetamol in patients with chronic myelogenous leukaemia (CML).</P><P><B>METHODS</B> Patients (<I>n</I>= 12) received a single oral dose of acetaminophen 1000 mg on day 1 (control). On days 2–8, imatinib 400 mg was administered daily. On day 8 (treatment), another 1000 mg dose of paracetamol was administered 1 h after the morning dose of imatinib 400 mg. Blood and urine samples were collected for bioanalytical analyses.</P><P><B>RESULTS</B> The area under the plasma concentration–time curve (AUC) for paracetamol, paracetamol glucuronide and paracetamol sulphate under control conditions was similar to that after treatment with imatinib; the 90% confidence interval of the log AUC ratio was within 0.8 to 1.25. Urinary excretion of paracetamol, paracetamol glucuronide and paracetamol sulphate was also unaffected by imatinib. The pharmacokinetics of paracetamol and imatinib in Korean patients with CML were similar to previous pharmacokinetic results in white patients with CML. Co‐administration of a single dose of paracetamol and multiple doses of imatinib was well tolerated and safety profiles were similar to those of either drug alone.</P><P><B>CONCLUSIONS</B> The pharmacokinetics of paracetamol and its major metabolites in the presence of imatinib were similar to those of the control conditions and the combination was well tolerated. These findings suggest that imatinib can be safely administered with paracetamol without dose adjustment of either drug.</P>
Use of Amplatz® canine duct occluder for closing a patent ductus arteriosus in a small-sized dog
Damin Jeong,Minhee Kang,Changmin Lee,Seunggon Kim,Sahee Min,Taeyeun Hahn,Heemyung Park 충북대학교 동물의학연구소 2014 Journal of Biomedical and Translational Research Vol.15 No.3
A 2-year-old intact female pomeranian dog presented dyspnea, labored breathing, cough, exercise intolerance, machinery heart murmur, and precordial thrill. A left-to-right patent ductus arteriosus (PDA) was diagnosed based on two-dimensional echocardiography, thoracic radiography, electrocardiography, and blood work. An angiography was performed to accurately evaluate the size and shape of the duct. An interventional approach for transcatheterial occlusion of the PDA was achieved using an Amplatz® Canine Duct Occluder (ACDO), which is a commercially available ductal occluding device. Due to the limited size of the dog’s femoral artery, a device smaller [125% of minimal ductal diameter (MDD); recommended size: 150~200% of MDD] than recommended was mounted. After placement of the ACDO, precordial thrill and continuous heart murmur disappeared, and the patient was discharged the next day after stabilization with O2 supply. Upon follow up examination, dyspnea, labored breathing, cough, exercise intolerance, and cardiomegaly were improved with no complications after the procedure. The ACDO was well maintained in position. This case represents successful clinical application of the Amplatz® Canine Duct Occluder to achieve closure of a PDA using a slightly smaller device than the recommended size.
Use of Amplatz® canine duct occluder for closing a patent ductus arteriosus in a small-sized dog
Damin Jeong, Minhee Kang, Changmin Lee, Seunggon Kim, Sahee Min, Taeyeun Hahn, Heemyung Park 충북대학교 동물의학연구소 2014 Journal of Biomedical and Translational Research Vol.15 No.3
A 2-year-old intact female pomeranian dog presented dyspnea, labored breathing, cough, exercise intolerance, machinery heart murmur, and precordial thrill. A left-to-right patent ductus arteriosus (PDA) was diagnosed based on two-dimensional echocardiography, thoracic radiography, electrocardiography, and blood work. An angiography was performed to accurately evaluate the size and shape of the duct. An interventional approach for transcatheterial occlusion of the PDA was achieved using an Amplatz® Canine Duct Occluder (ACDO), which is a commercially available ductal occluding device. Due to the limited size of the dog’s femoral artery, a device smaller [125% of minimal ductal diameter (MDD); recommended size: 150~200% of MDD] than recommended was mounted. After placement of the ACDO, precordial thrill and continuous heart murmur disappeared, and the patient was discharged the next day after stabilization with O2 supply. Upon follow up examination, dyspnea, labored breathing, cough, exercise intolerance, and cardiomegaly were improved with no complications after the procedure. The ACDO was well maintained in position. This case represents successful clinical application of the Amplatz® Canine Duct Occluder to achieve closure of a PDA using a slightly smaller device than the recommended size.